Eli Lilly
Eli Lilly
LLY | NYSE · Health Care
About Eli Lilly (LLY)
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
- CEO
- David A. Ricks
- Employees
- 50K
- Headquarters
- United States
- Sector
- Health Care
- Industry
- PHARMACEUTICAL PREPARATIONS
- Exchange
- NYSE
- Token
- LLYc
- Chain
- Base
Stats
- Market cap
- $1.3T
- Revenue (TTM)
- $86.5B
- EPS (TTM)
- $30.81
- Price / earnings ratio
- 46.02x
- Debt / equity
- 1.23x
- Gross margin
- 83.88%
- Net margin
- 26.44%
- Current ratio
- 1.39x
- Next earnings
- Feb 3, 2027
- Yesterday's volume *
- 3.6M
- Avg. daily volume *
- 2.6M
- Open
- $1,440.00
- Previous close
- $1,409.38
- Today's range
- $1,401.59 – $1,445.96
- Yesterday's range *
- $1,401.59 – $1,445.96
- 52 week range
- $850.51 – $1,449.68
- Dividend yield
- 0.47%
* Derived from daily price history
Earnings
Eli Lilly reported earnings per share (EPS) of $7.48 on Oct 29 '26, beating estimates of $5.71 by 31.00%. Eli Lilly is expected to release its next earnings on Feb 3 '27, with an EPS estimate of $11.20.
Price targets
What analysts think LLY stock price will be.
Stock rating
What analysts recommend for LLY stock, on a scale from 1(buy) to 5(sell).
Based on 31 analysts
Eli Lilly Stock News
MGH, Brigham, other hospitals sue Eli Lilly, alleging ‘extortion’ in drug discount program
boston.com ·
Treasury's Refunding Details Are Up Next as Five Large Companies Report Higher Revenue
prnewswire.com ·
Tech Moves: Microsoft loses a CVP to AWS and gains one from Alteryx; Lila Bio and BECU name execs
geekwire.com ·
Forget Nvidia: Eli Lilly Will Become “the Most Valuable Company in the World,” Says Macro Investor
finance.yahoo.com ·
All Ecosystem Coins
Coins paired with LLY
Buying LLYc